ArticleJournal of the American Heart Association2025
Advanced Glycation End-Product Carboxymethyl-Lysine and Incident Heart Failure and Atrial Fibrillation in Older Adults.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review.Endocrinology, diabetes & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAdvanced glycation end-products result from chemical modification of proteins under conditions of hyperglycemia or oxidative stress common with advancing age. Advanced glycation end-product (AGE) formation alters vascular and cardiac structure and function, yet the prospective associations of circulating AGEs with heart failure (HF) and atrial fibrillation (AF) have not been studied.
methodsWe evaluated the associations of serum N
resultsAmong 2685 eligible participants (age 77±5; 63% women; 17% with diabetes), 832 HF and 1016 AF events occurred over a median follow-up of 9 years. After adjustment for potential confounders, serum CML was associated with a higher risk of incident HF and AF (hazard ratio per SD, 1.10 and 1.09 [95% CI, 1.02-1.17 and 1.02-1.16], respectively). The association with AF was attenuated and nonsignificant after adjusting for estimated glomerular filtration rate and urine albumin-creatinine ratio. The CML-HF relation was similarly attenuated after adjusting for time-updated myocardial infarction. Both associations were nonsignificant after adjusting for natriuretic peptides or excluding those with elevated levels at baseline. Secondary analyses of incident HF subtypes or baseline cardiac mechanics showed no significant associations.
conclusionsIn older adults, serum CML was prospectively associated with higher risk of HF and AF independent of potential confounders, with evidence of attenuation by certain putative mediators. AGEs and AGE-countering therapies merit additional evaluation in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.